Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren’s syndrome-associated interstitial lung disease
Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system...
Saved in:
Published in | Arthritis research & therapy Vol. 24; no. 1; pp. 121 - 9 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
23.05.2022
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1478-6362 1478-6354 1478-6362 |
DOI | 10.1186/s13075-022-02811-z |
Cover
Loading…
Abstract | Objective
Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes.
Methods
Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry.
Results
The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS.
Conclusion
Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. |
---|---|
AbstractList | Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Abstract Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Objective Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes. Methods Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry. Results The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS. Conclusion Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. Keywords: Primary Sjogren syndrome (pSS), Interstitial lung disease (ILD), Th2 cells, Th1/Th2 ratio Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes.OBJECTIVEPrimary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the involvement and dysfunction of multiple organs and tissues. Interstitial lung disease (ILD) is the most common type of respiratory system damage. This study ascertained the factors related to ILD in patients with pSS (pSS-ILD), such as altered levels of circulating lymphocyte subtypes.Eighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry.METHODSEighty healthy controls and 142 patients diagnosed with pSS were included. The pSS patients were classified into groups with pSS-ILD or pSS without ILD (pSS-non-ILD). Baseline clinical and laboratory data were collected for all subjects, including the levels of lymphocytes measured by modified flow cytometry.The pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS.RESULTSThe pSS-ILD patients were older, had higher ESSDAI scores, had higher positivity rates for anti-SSB and anti-Ro52 antibodies, and had more frequent symptoms of respiratory system involvement than pSS-non-ILD patients. pSS-ILD patients had the lowest Th2 cell counts among the three groups. Although the absolute numbers of Treg and NK cells were lower in pSS patients with and without ILD than in the healthy controls, there was no significant difference between the two pSS groups. The Th1/Th2 ratio was significantly higher in patients with ILD than in patients without ILD. Further analysis showed that older age (OR=1.084), lower Th2 count (OR=0.947), higher Th1/Th2 ratio (OR=1.021), and positivity for anti-SSB (OR=3.620) and anti-Ro52 (OR=5.184) antibodies were associated with the occurrence of ILD in patients with pSS.Decreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients.CONCLUSIONDecreased circulating Th2 cells and an elevated Th1/Th2 ratio may be the immunological mechanism underlying the development of ILD in pSS patients. |
ArticleNumber | 121 |
Audience | Academic |
Author | Tang, Yu-Ping Liu, Guang-Ying Han, Xiao-Lei Shi, Lei Wang, Jia Guo, Hong-Xia |
Author_xml | – sequence: 1 givenname: Lei surname: Shi fullname: Shi, Lei email: 56443961@qq.com organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University – sequence: 2 givenname: Jia surname: Wang fullname: Wang, Jia organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University – sequence: 3 givenname: Hong-Xia surname: Guo fullname: Guo, Hong-Xia organization: Department of Cardiology, The Second Hospital of Shanxi Medical University – sequence: 4 givenname: Xiao-Lei surname: Han fullname: Han, Xiao-Lei email: sydey_hxl@sina.com organization: Department of Mental Health, The Second Hospital of Shanxi Medical University – sequence: 5 givenname: Yu-Ping surname: Tang fullname: Tang, Yu-Ping organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University – sequence: 6 givenname: Guang-Ying surname: Liu fullname: Liu, Guang-Ying organization: Department of Rheumatology, The Second Hospital of Shanxi Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35606782$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstu1TAURSNURB_wAwxQJCZM0voRJ84EqbriUakSA8rYcuyT1FeJXeykqB0x5g_4Pb6Ecx-lvRWqoijO8drbPvY-zPZ88JBlryk5plRWJ4lyUouCMIavpLS4fZYd0LKWRcUrtvdgvJ8dprQkSDasfJHtc1GRqpbsIPu1cNHMg56c7_OLS5YbGIY8gp3N5ILPtbdYpierKTe2etDeQK4j5CbECCgEm_9w02V-Fd2o403-dRn6CP7Pz98pTzfexjBCoVMKxq1h5yeIaXKT00M-zLisdQl0gpfZ804PCV5tv0fZt48fLhafi_Mvn84Wp-eFEbyeCitIadvSdFRie5WoOjBat3WH_Qgt6k40mrcN_gsuRck4Y52Vhlai5aCp5EfZ2cbXBr1U222roJ1aF0LslY6TMwMo0lIQhFpBO1M2gjam5K2wpRCMt7Um6PV-43U1tyNYA36Ketgx3Z3x7lL14Vo1lAkpGjR4tzWI4fsMaVKjS6s70B7CnBSrKtmQWpIS0beP0GWYo8ejQqqWtJSS8Huq19iA813Adc3KVJ3WpCo5YjVSx_-h8LEwOoMx6xzWdwRvHjb6r8O7JCEgN4CJIaUInTJu0qsMobMbFCVqFVq1Ca3CKKp1aNUtStkj6Z37kyK-ESWEfQ_x_jSeUP0FJsgAiA |
CitedBy_id | crossref_primary_10_1016_j_autrev_2024_103600 crossref_primary_10_1136_bmjresp_2023_002076 crossref_primary_10_3389_fimmu_2024_1345381 crossref_primary_10_1080_03007995_2023_2281501 crossref_primary_10_1186_s12865_023_00550_7 crossref_primary_10_12968_hmed_2024_0572 crossref_primary_10_1093_rheumatology_kead070 crossref_primary_10_2147_JAA_S383128 crossref_primary_10_1167_iovs_64_12_7 crossref_primary_10_1016_j_heliyon_2024_e31751 crossref_primary_10_1097_HC9_0000000000000269 crossref_primary_10_3389_fmolb_2024_1448946 crossref_primary_10_3389_fimmu_2024_1435525 crossref_primary_10_1007_s10753_022_01747_5 |
Cites_doi | 10.1111/j.1748-5827.2011.01024.x 10.3389/fimmu.2019.01327 10.1136/annrheumdis-2016-210571 10.1371/journal.pone.0073774 10.1164/rccm.2009-040GL 10.2353/ajpath.2006.051160 10.1007/s00296-012-2561-7 10.1136/ard.61.6.554 10.1136/annrheumdis-2018-213036 10.1016/j.reuma.2015.10.010 10.1186/s12952-017-0069-0 10.1136/ard.2009.114264 10.1007/s10067-018-4289-6 10.1177/2040622320916014 10.1007/s00296-009-1152-8 10.1038/nri911 10.1093/rheumatology/kes311 10.1042/BST0350661 10.1177/2040622320944802 10.1136/ard.59.9.709 10.3760/cma.j.issn.0578-1426.2018.08.005 10.1186/ar3097 10.1136/ard.2005.049924 10.1002/art.24435 10.1016/j.cyto.2014.06.008 10.1158/1055-9965.EPI-04-0624 10.1111/1756-185X.13334 10.1016/j.jaut.2009.10.004 10.21037/jtd.2018.03.120 10.1016/j.lab.2006.01.001 10.1007/s10238-020-00623-6 10.1046/j.1365-2249.1998.00705.x 10.1378/chest.128.4.2971 10.1136/jcp.2003.015495 10.1136/bmj.h6819 10.1164/rccm.200502-244OC 10.1111/cei.12341 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13075-022-02811-z |
DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1478-6362 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_0b1e501d51fc49519c43b5d45523b7a0 PMC9125859 A706434887 35606782 10_1186_s13075_022_02811_z |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: Doctoral Fund of the Second Hospital of Shanxi Medical University grantid: No.202001-4 – fundername: Natural Science Research Project of Shanxi Province grantid: No. 20210302123281 – fundername: ; grantid: No. 20210302123281 – fundername: ; grantid: No.202001-4 |
GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABUWG ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ AAYXX ALIPV CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 IAO IHR NPM Z7U PMFND 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c537t-d504db4cf18478656fecaab7f7825a57f59a3b97f7538542322fd8c165b3ea183 |
IEDL.DBID | C6C |
ISSN | 1478-6362 1478-6354 |
IngestDate | Wed Aug 27 01:32:23 EDT 2025 Thu Aug 21 18:25:50 EDT 2025 Fri Sep 05 03:26:07 EDT 2025 Fri Jul 25 04:16:30 EDT 2025 Tue Jun 17 21:43:41 EDT 2025 Tue Jun 10 20:43:54 EDT 2025 Wed Feb 19 02:23:56 EST 2025 Tue Jul 01 04:00:59 EDT 2025 Thu Apr 24 22:58:15 EDT 2025 Sat Sep 06 07:28:17 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Interstitial lung disease (ILD) Primary Sjogren syndrome (pSS) Th2 cells Th1/Th2 ratio |
Language | English |
License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c537t-d504db4cf18478656fecaab7f7825a57f59a3b97f7538542322fd8c165b3ea183 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://doi.org/10.1186/s13075-022-02811-z |
PMID | 35606782 |
PQID | 2678148803 |
PQPubID | 42876 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0b1e501d51fc49519c43b5d45523b7a0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9125859 proquest_miscellaneous_2668907804 proquest_journals_2678148803 gale_infotracmisc_A706434887 gale_infotracacademiconefile_A706434887 pubmed_primary_35606782 crossref_citationtrail_10_1186_s13075_022_02811_z crossref_primary_10_1186_s13075_022_02811_z springer_journals_10_1186_s13075_022_02811_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-05-23 |
PublicationDateYYYYMMDD | 2022-05-23 |
PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-23 day: 23 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Arthritis research & therapy |
PublicationTitleAbbrev | Arthritis Res Ther |
PublicationTitleAlternate | Arthritis Res Ther |
PublicationYear | 2022 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | M Polihronis (2811_CR39) 1998; 114 AJ Tyndall (2811_CR8) 2010; 69 MI Christodoulou (2811_CR12) 2010; 34 T Wang (2811_CR9) 2016; 34 A Suarez (2811_CR40) 2006; 65 B Efared (2811_CR1) 2017; 16 L Shi (2811_CR32) 2020; 20 SC Mathai (2811_CR5) 2016; 352 V Yazisiz (2811_CR24) 2010; 30 R Zhang (2811_CR22) 2014; 69 S Gupta (2811_CR7) 2019; 10 Q Wang (2811_CR17) 2018; 57 Y Wang (2811_CR21) 2018; 10 H Gao (2811_CR27) 2018; 21 Y Izumi (2811_CR33) 2006; 147 BK Davidson (2811_CR4) 2000; 59 P Pignatti (2811_CR31) 2006; 173 Z Amoura (2811_CR3) 2005; 14 O Palm (2811_CR23) 2013; 52 LA Aqrawi (2811_CR26) 2014; 177 L Zhang (2811_CR38) 2013; 33 J Wang (2811_CR18) 2020; 11 CH Shiboski (2811_CR15) 2017; 76 M Miao (2811_CR13) 2018; 77 J Gauldie (2811_CR37) 2007; 35 C Vitali (2811_CR14) 2002; 61 Y Enomoto (2811_CR20) 2013; 8 JA Trapani (2811_CR34) 2002; 2 G Raghu (2811_CR16) 2011; 183 SA Papiris (2811_CR29) 2005; 128 T Kimura (2811_CR28) 2006; 169 H Miyazaki (2811_CR35) 2004; 57 IG Luzina (2811_CR36) 2009; 60 DB Chandler (2811_CR10) 1983; 112 R Menor Almagro (2811_CR25) 2016; 12 FV Castelino (2811_CR2) 2010; 12 L Shi (2811_CR19) 2020; 11 F Meloni (2811_CR30) 2009; 27 X Dong (2811_CR6) 2018; 37 RS Thrall (2811_CR11) 1984; 129 NT Whitley (2811_CR41) 2011; 52 |
References_xml | – volume: 52 start-page: 70 issue: 2 year: 2011 ident: 2811_CR41 publication-title: J Small Anim Pract doi: 10.1111/j.1748-5827.2011.01024.x – volume: 10 start-page: 1327 year: 2019 ident: 2811_CR7 publication-title: Front Immunol doi: 10.3389/fimmu.2019.01327 – volume: 76 start-page: 9 issue: 1 year: 2017 ident: 2811_CR15 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-210571 – volume: 8 start-page: e73774 issue: 9 year: 2013 ident: 2811_CR20 publication-title: PLoS One doi: 10.1371/journal.pone.0073774 – volume: 183 start-page: 788 issue: 6 year: 2011 ident: 2811_CR16 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.2009-040GL – volume: 169 start-page: 96 issue: 1 year: 2006 ident: 2811_CR28 publication-title: Am J Pathol doi: 10.2353/ajpath.2006.051160 – volume: 33 start-page: 1403 issue: 6 year: 2013 ident: 2811_CR38 publication-title: Rheumatol Int doi: 10.1007/s00296-012-2561-7 – volume: 61 start-page: 554 issue: 6 year: 2002 ident: 2811_CR14 publication-title: Ann Rheum Dis doi: 10.1136/ard.61.6.554 – volume: 77 start-page: 1838 issue: 12 year: 2018 ident: 2811_CR13 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213036 – volume: 12 start-page: 256 issue: 5 year: 2016 ident: 2811_CR25 publication-title: Reumatol Clin doi: 10.1016/j.reuma.2015.10.010 – volume: 16 start-page: 4 issue: 1 year: 2017 ident: 2811_CR1 publication-title: J Negat Results Biomed doi: 10.1186/s12952-017-0069-0 – volume: 69 start-page: 1809 issue: 10 year: 2010 ident: 2811_CR8 publication-title: Ann Rheum Dis doi: 10.1136/ard.2009.114264 – volume: 37 start-page: 2981 issue: 11 year: 2018 ident: 2811_CR6 publication-title: Clin Rheumatol doi: 10.1007/s10067-018-4289-6 – volume: 34 start-page: 587 issue: 4 year: 2016 ident: 2811_CR9 publication-title: Clin Exp Rheumatol – volume: 11 start-page: 1 year: 2020 ident: 2811_CR18 publication-title: Ther Adv Chronic Dis doi: 10.1177/2040622320916014 – volume: 30 start-page: 1317 issue: 10 year: 2010 ident: 2811_CR24 publication-title: Rheumatol Int doi: 10.1007/s00296-009-1152-8 – volume: 2 start-page: 735 issue: 10 year: 2002 ident: 2811_CR34 publication-title: Nat Rev Immunol doi: 10.1038/nri911 – volume: 52 start-page: 173 issue: 1 year: 2013 ident: 2811_CR23 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kes311 – volume: 35 start-page: 661 issue: Pt 4 year: 2007 ident: 2811_CR37 publication-title: Biochem Soc Trans doi: 10.1042/BST0350661 – volume: 112 start-page: 170 issue: 2 year: 1983 ident: 2811_CR10 publication-title: Am J Pathol – volume: 11 start-page: 204062232094480 year: 2020 ident: 2811_CR19 publication-title: Ther Adv Chronic Dis doi: 10.1177/2040622320944802 – volume: 59 start-page: 709 issue: 9 year: 2000 ident: 2811_CR4 publication-title: Ann Rheum Dis doi: 10.1136/ard.59.9.709 – volume: 57 start-page: 558 issue: 8 year: 2018 ident: 2811_CR17 publication-title: Chi J Intern Med doi: 10.3760/cma.j.issn.0578-1426.2018.08.005 – volume: 12 start-page: 213 issue: 4 year: 2010 ident: 2811_CR2 publication-title: Arthritis Res Ther doi: 10.1186/ar3097 – volume: 65 start-page: 1512 issue: 11 year: 2006 ident: 2811_CR40 publication-title: Ann Rheum Dis doi: 10.1136/ard.2005.049924 – volume: 60 start-page: 1530 issue: 5 year: 2009 ident: 2811_CR36 publication-title: Arthritis Rheum doi: 10.1002/art.24435 – volume: 69 start-page: 289 issue: 2 year: 2014 ident: 2811_CR22 publication-title: Cytokine doi: 10.1016/j.cyto.2014.06.008 – volume: 14 start-page: 1279 issue: 5 year: 2005 ident: 2811_CR3 publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-04-0624 – volume: 21 start-page: 1423 issue: 7 year: 2018 ident: 2811_CR27 publication-title: Int J Rheum Dis doi: 10.1111/1756-185X.13334 – volume: 34 start-page: 400 issue: 4 year: 2010 ident: 2811_CR12 publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.10.004 – volume: 10 start-page: 2108 issue: 4 year: 2018 ident: 2811_CR21 publication-title: J Thorac Dis doi: 10.21037/jtd.2018.03.120 – volume: 147 start-page: 242 issue: 5 year: 2006 ident: 2811_CR33 publication-title: J Lab Clin Med doi: 10.1016/j.lab.2006.01.001 – volume: 20 start-page: 393 issue: 3 year: 2020 ident: 2811_CR32 publication-title: Clin Exp Med doi: 10.1007/s10238-020-00623-6 – volume: 114 start-page: 485 issue: 3 year: 1998 ident: 2811_CR39 publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1998.00705.x – volume: 129 start-page: 279 issue: 2 year: 1984 ident: 2811_CR11 publication-title: Am Rev Respir Dis – volume: 128 start-page: 2971 issue: 4 year: 2005 ident: 2811_CR29 publication-title: Chest doi: 10.1378/chest.128.4.2971 – volume: 57 start-page: 1292 issue: 12 year: 2004 ident: 2811_CR35 publication-title: J Clin Pathol doi: 10.1136/jcp.2003.015495 – volume: 352 start-page: h6819 year: 2016 ident: 2811_CR5 publication-title: BMJ doi: 10.1136/bmj.h6819 – volume: 173 start-page: 310 issue: 3 year: 2006 ident: 2811_CR31 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200502-244OC – volume: 27 start-page: 765 issue: 5 year: 2009 ident: 2811_CR30 publication-title: Clin Exp Rheumatol – volume: 177 start-page: 244 issue: 1 year: 2014 ident: 2811_CR26 publication-title: Clin Exp Immunol doi: 10.1111/cei.12341 |
SSID | ssj0022924 |
Score | 2.4622579 |
Snippet | Objective
Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and... Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and the... Objective Primary Sjogren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and... Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine glands and... Abstract Objective Primary Sjogren’s syndrome (pSS) is a heterogeneous chronic autoimmune disorder characterized by lymphocyte infiltration of the exocrine... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 121 |
SubjectTerms | Age Antibodies Arthritis Blood Complications and side effects Connective tissue Development and progression Exocrine glands Flow cytometry Health aspects Immunology Interstitial lung disease (ILD) Laboratories Lung diseases Lung diseases, Interstitial Lymphocytes Measurement Medical diagnosis Medicine Medicine & Public Health Mortality Orthopedics Pathogenesis Primary Sjogren syndrome (pSS) Research Article Respiratory system Rheumatology Risk factors Sjogren's syndrome T cells Th1/Th2 ratio Th2 cells |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p9AQUZC4gDRxrEdx8dSUVVI5UIr9Wb5L3RRm0W720tPPfcNeD2ehBnHWZoi4MJhDxuPI9szHs8X298Q8rrhvhONjKWuQwsAhcXSBs7LSkTBXYxWJp6Cg0_N_pH4eCyPr6X6wjNhAz3wMHCzyrEoKxYk6zwE80x7eIcMQgKCcsomtA5r3gimMtSqAVaMV2TaZrYCT63wJnINv5ax8mKyDCW2_t998rVF6eaByRu7pmkx2rtH7uYoku4Mrb9PbsX-Abl9kPfJH5Kr3fnSp8Rc_Rd6eFJT_D5Pl0jTioqgtg_wmM2waH7m8Hijj9QuI_WYrQMqxkDxEy39NrBR0M9fF4DM-x-X31d0ZDkobdYtCCPtxBLPHYA901PwIDRv_TwiR3sfDnf3y5x1ofSSq3UZZCWCE74D7KdaCPe66K11qoNYQlqpOqktdxr-g6-UuM9bd6H1rJGORwse4jHZ6hd9fEqoVZo5W3Ved1q4StlOBBGdZsE3gMtVQdioBOMzJTlmxjg1CZq0jRkUZ0BxJinOXBTk7aZOHoK_Sr9H3W4kkUw7PQATM9nEzL9MrCBv0DIMTnlonrf55gJ0EsmzzI7CuA48IXRoeyIJU9VPi0fbMtlVrEzdIOsYuFFekFebYqyJx9_6uDhHmabVFXJFFeTJYIqbLnGIWeEVdUHUxEgnfZ6W9POTRCSuIbptpS7Iu9GcfzXrz2P67H-M6XNyp07TUZY13yZb6-V5fAHh3dq9TDP5J8FsTC4 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELZgKyEuiH9SCjISEgeINk7sOD6htmpVIbVC0Eq9Wf5Lu6gkbXZ76Ykzb8Dr8STMZJ0tKaKHHBLbUZz5PJ7x2N8Q8rYsXM1LEVKV-wocFBZS44sizXjghQ3BiJ6nYP-g3Dvin47FcVxwm8dtlYNO7BW1bx2ukU_zEsmZAG3Fx_OLFLNGYXQ1ptC4S9ZABVdiQta2dg4-f1m5XLlaprXl4CvB1MqHYzNVOZ2D9pZ4OjmHq2IsvRpNTT2D_796-q-J6uYmyhuR1H6C2n1IHkTLkm4uofCI3AnNY3JvP8bOn5Cf27PO9cm6mhN6eJpTXLOnHVK3onCoaTw8ZlMsmn23uOXRBWq6QB1m8ICGwVNctqXnS4YK-vVbC9568_vHrzkdmA9SE-UNlZGKosO9CIBxegZahcZw0FNytLtzuL2XxkwMqROFXKReZNxb7mrwB2UFJmAdnDFW1mBfCCNkLZQprIJ70J8CY7957SvHSmGLYEBrPCOTpm3CC0KNVMyarHaqVtxm0tTc82AV864EX10mhA1C0C7SlGO2jDPduytVqZeC0yA43QtOXyXk_apN_AW31t5C2a5qIsF2_6DtTnQcrzqzLIiMecFqBz4kUw6gKzwX4LhbabKEvENkaFQD8HnOxNMM0Ekk1NKbEm09wCt0aGNUE4avGxcP2NJRfcz1NdgT8mZVjC1xS1wT2kusU1YqQ_6ohDxfQnHVpQLsWHhFnhA5Aumoz-OSZnbak4srsHgroRLyYYDz9Wf9_5-u396Ll-R-3g80kebFBpksusvwCoy5hX0dR-wf7ntHyw priority: 102 providerName: ProQuest |
Title | Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren’s syndrome-associated interstitial lung disease |
URI | https://link.springer.com/article/10.1186/s13075-022-02811-z https://www.ncbi.nlm.nih.gov/pubmed/35606782 https://www.proquest.com/docview/2678148803 https://www.proquest.com/docview/2668907804 https://pubmed.ncbi.nlm.nih.gov/PMC9125859 https://doaj.org/article/0b1e501d51fc49519c43b5d45523b7a0 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZoKyEuiDeBsjISEgeIGidxHB-3q1YVUisEXWlvll-hW5Usym4vPXHmH_D3-CXMeJ2lKQ-JQyIlHkex5-EZj_2ZkFdVYZuy4j6VuashQGE-1a4o0qz0ZWG81zzgFByfVEfT8t2MzyJMDu6FuZ6_Z3W1twQbK3APcQ5XzVh6tUV2OOKMYWK2mmyCqxwCiX5TzB_rDQaegM__uxW-NgzdXCJ5I08ahp_De-Ru9BvpeM3o--SWbx-Q28cxM_6QfJvMOxuO4mo_0dOznOKMPO0QmBW7nurWwWu2h0XzzwYXNFpPdeepxfM5oKJ3FCdl6Zc1_gT9eL6AWLz98fX7kva4BqmO3ARiBJrocKUBSDC9AJtBY7LnEZkeHpxOjtJ4zkJqeSFWqeNZ6UxpG4j2RA0OXuOt1kY04D1wzUXDpS6MhGewjhwzu3njassqbgqvwSY8JtvtovVPCdVCMqOzxspGliYTuild6Y1kzlYQiYuEsJ4JykYQcjwL40KFYKSu1JpxChinAuPUVULebOrELvgn9T7ydkOJ8NnhBUiVitqoMsM8z5jjrLEQITJpQTC5KzmE5UboLCGvUTIUKjn8ntVxrwI0EuGy1FigJwe2Dxq0O6AE5bTD4l62VDQOS5VXiDMGhrNIyMtNMdbEBW-tX1wiTVXLDNGhEvJkLYqbJhXgpcIn8oSIgZAO2jwsaednATpcgj9bc5mQt704__qtv_fps_8jf07u5EHxeJoXu2R71V36F-C6rcyIbImZGJGd_YOT9x9GQYNHYRoE7tN8_BOTTkIy |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKKwEbxJtAASOBWEA0sRMn8QKhtrSa0s4IwVTqzji2Mx1UMiUzFaIr1vwBP8FH8SXcm8eUFNFdF1kkfijOfefa5xLyNA5NHsXC-ZLbFAIU5nxtw9APIheFmXNaVDgFg2Hc34ve7ov9JfKrPQuD2ypbnVgpajs1-I-8x2MEZwJuC18fffGxahRmV9sSGjVb7LhvXyFkm73afgP0fcb51uZoo-83VQV8I8Jk7lsRRDaLTA6xTZKCO5M7o3WW5GArhRZJLqQOMwn3oAsE5jF5blPDYpGFToMEwLyXyAq4GRKkaGV9c_ju_SLE47Iuowsz-2DKo_aYThr3ZmAtEjwNzeFKGfNPOqawqhjwr134yzCe3bR5JnNbGcSt6-Ra48nStZr1bpAlV9wklwdNrv4W-bExKU1VHKwY09EBp5gjoCVCxSIzUF1YeMx62DT5nOEWS-OoLh01WDEEBjpL8TcxPaoRMeiHT9Nx6Yrf33_OaIu04OuGv6AzQl-UuPcBZIoeghajTfrpNtm7EBrdIcvFtHD3CNWJZJkOciNzGWVBovPIRi6TzJo4ACvhEdYSQZkGFh2rcxyqKjxKY1UTTgHhVEU4deKRF4sxzSc4t_c60nbREwG9qwfTcqwa_aCCjDkRMCtYbiBmZdKAqAgbCcHDLNGBR54jZyhUO_B6RjenJ2CRCOCl1hL0LUE-YEGrnZ6gLky3ueUt1airmToVLo88WTTjSNyCV7jpMfaJUxkgXpVH7tasuFhSCH4zTME9knSYtLPmbksxOajAzCV42KmQHnnZsvPpa_3_m94_fxWPyZX-aLCrdreHOw_IVV4JnfB5uEqW5-WxewiO5Dx71EgvJR8vWmH8AfWDhFY |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZgK1VcEG8CBYyExAGijZM4jo9LYVUWWiG1lXqz_GwXlWyV3V564sw_4O_xS5jJY2nKQ-Kwh8TjVZx5eCYz85mQF0VmQ15wH8vUlRCgMB9rl2Vxkvs8M95r3uAU7O4VO4f57IgfXerib6rd-5Rk29OAKE3VanzmQqviZTFeguUV2Fmcwq9kLL64TjbKAtyHEdmYTGb7s3XQlUKA0TfL_HHmYENqcPt_t86XtqerpZNX8qfNtjS9RW52_iSdtAJwm1zz1R2yudtlzO-Sb9vz2jZHdFXH9OAkpfilntYI2IosobpycJuNcWj-xWCho_VU155aPLcDJnpH8WMtPWtxKej-5wXE6NWPr9-XtMc7iHXHZSBGAIoaKxBAsukp2BLaJYHukcPpu4Ptnbg7fyG2PBOr2PEkdya3AaJAUYLjF7zV2ogAXgXXXAQudWYkXIPV5JjxTYMrLSu4ybwGW3GfjKpF5R8SqoVkRifByiBzkwgdcpd7I5mzBUToIiKsZ4KyHTg5npFxqpogpSxUyzgFjFMN49RFRF6t53Sv4J_Ub5C3a0qE1W5uLOpj1WmpSgzzPGGOs2AhcmTSgsByl3MI143QSUReomQoVH54PKu7HgZYJMJoqYlADw9sIixoa0AJSmuHw71sqc5oLFVaIP4YGNQsIs_XwzgTC-EqvzhHmqKUCaJGReRBK4rrJWXgvcJfpBERAyEdrHk4Us1PGkhxCX5uyWVEXvfi_Oux_v5OH_0f-TOy-entVH18v_fhMbmRNjrI4zTbIqNVfe6fgHe3Mk87Bf4JITRKbg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+Th2+cell+reduction+and+Th1%2FTh2+imbalance+are+correlated+with+primary+Sjogren%27s+syndrome-associated+interstitial+lung+disease&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Shi%2C+Lei&rft.au=Wang%2C+Jia&rft.au=Guo%2C+Hong-Xia&rft.au=Han%2C+Xiao-Lei&rft.date=2022-05-23&rft.eissn=1478-6362&rft.volume=24&rft.issue=1&rft.spage=121&rft_id=info:doi/10.1186%2Fs13075-022-02811-z&rft_id=info%3Apmid%2F35606782&rft.externalDocID=35606782 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |